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Structural racism is endemic in the United States and
causes inequitable health outcomes that have been amplified throughout the COVID-19 pandemic.1,2 Non-Hispanic
Black, Hispanic/Latino, and Native American individuals
have been disproportionately affected, and are twice as
likely to be hospitalized or die from COVID-19 or related
morbidities when compared to White Americans.2 Social
determinants of health inequities contribute to these disparate outcomes, given that minoritized individuals are
more likely to occupy essential worker roles and to live in
high-density settings.1 Despite their higher risk of severe
COVID-19 illness, racially and ethnically minoritized individuals are less likely to receive potentially lifesaving
COVID-19 therapeutics.3 While several state health departments attempted to implement race-conscious interventions and narrow the disparities, these efforts have been
met with fallacious claims of ‘reverse racism’ and the
reversal of the proposed implementations.3

Barriers to healthcare access with racially and
ethnically minoritized groups
Economic and environmental injustices, psychosocial
trauma, state-sanctioned violence, separation from
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traditional lands, and political exclusion through voting
restrictions are key contributors to the lack of access to
the healthcare system that racially and ethnically
minoritized groups experience.1 American Indian/
Alaska Native, Hispanic/Latino, and Black Americans
have higher uninsured rates at 22%, 20%, and 12%,
respectively, when compared to 7% of White Americans.4 States electing to not expand Medicaid have further exacerbated these inequities, as Medicaid
expansion has been associated with more equitable
access to care and improved health outcomes.4 Racially
and ethnically minoritized individuals are also more
likely to live in a primary care provider desert- where
there is on average, one full-time provider for over
10,000 individuals.5 Inevitably, this lack of healthcare
providers alongside systemic barriers perpetuates the
recognized COVID-19 inequities, including the access
to preventive care as well as novel therapeutics to manage disease severity.
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The need for federal initiatives that ensure
equitable access to COVID-19 antivirals
In March 2022, the Biden Administration announced
the nationwide “Test to Treat” initiative as part of the
National COVID-19 Preparedness Plan.6 This initiative
aims to grant Americans who test positive for SARSCoV-2, rapid access to oral antivirals (i.e., molnupiravir,
nirmatrelvir/ritonavir) at pharmacy-based clinics and
federally qualified health centers (FQHCs), through
direct allocations from the Department of Health and
Human Services and the Office of the Assistant Secretary for Preparedness and Response.6 There are

1

Comment

approximately 1,375 FQHCs serving nearly 28 million
patients, and greater than 60% identify as a member
of a minoritized group.5 On the surface, this initiative has the potential to vastly improve the poor
COVID-19 outcomes observed in minoritized communities.
However, the “Test to Treat” plan in its current
design fails to address several key barriers to the access
of COVID-19 therapeutics recognized within minoritized communities. While FQHCs primarily serve a
minoritized patient base, these health centers are
unevenly distributed throughout the country.5 This
poses challenges in minoritized communities where
inequities in transportation significantly segregate these
individuals from accessing healthcare, stemming
from unreliable mass transit modalities and associated transportation cost.7 Additionally, patients must
be able to locate the FQHCs that will provide the
needed health services online.6 Similar to transportation, digital access inequities have been observed
within minoritized communities.7 Furthermore, the
lack of internet access was a noted limitation in
accessing the COVID-19 preventive therapeutics (vaccines) across minoritized groups.8 Consequently,
these gaps have persisted and, in some cases, widened within these communities.7 Therefore, FQHCs
as the main prescribing entities does not fully address
the current pattern in the inequitable distribution of
the novel COVID-19 oral therapies.5
Ideally, the 60,000 pharmacies in the U.S. could
work in tandem with the FQHCs to lessen the recognized inequities. Unfortunately, the plan—along with
the current Food and Drug Administration (FDA)
Emergency Use Authorizations (EUAs) specific to the
oral antivirals—omits pharmacists from the designated
list of prescribers able to test and provide patients with
these antivirals.6,9 The exclusion of pharmacists creates
unnecessary barriers to care, especially across minoritized groups. It also squanders the opportunity to leverage pharmacists’ ability to quickly establish low-barrier,
easily accessible (mobile/community) pharmacy
options.10 This would be significant in vulnerable areas
that have been disproportionately affected by COVID-19
inequities and would add an additional layer to COVID19 “pharmacoequity”. Nonetheless, if the “Test to Treat”
plan and/or specific EUAs were to be altered to include
pharmacists as authorized prescribers, it would be critical to ensure that prescribing practices remain collaborative between pharmacists and physician and/or
advanced practice providers. Thus, the development of
an interdisciplinary, rapid, bidirectional, communication mechanism regarding the prescribing of the
COVID-19 oral antivirals would be essential. Of further
note, the system may also aid in expediting the identification and treatment of a COVID-19 case. This would
not only mitigate the virus spread within minoritized

2

communities, but also prevent deleterious complications requiring hospitalization.

Conclusions
Though COVID-19 case rates have subsided in some
communities, the negative effects of the pandemic
remain among minoritized groups. The lack of prioritization of race and ethnicity within treatment algorithms for COVID-19 directed therapeutics will
inevitably translate to a widening of health equity
gaps. If correctly curated, federal programs like “Test
to Treat” can expand access to novel COVID-19 therapies; however, for that to succeed, it must acknowledge the barriers to effective and optimal patient
care within minoritized communities. Finally, we
call on professional healthcare organizations to collaborate to mitigate these barriers and collectively
lobby for improved patient outcomes rather than
individual organizational interests.
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